Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.49 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 4/20 | 0.46 |
| ▸ | CCR5 | P51681 | 4/20 | 0.46 |
| ▸ | CCR8 | P51685 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197885 | 0.88 | HSP90AA1 (0.66) | HSP90AA1NPC1RAB9ARUNX1CRHR1 | |
| SCHEMBL7241847 | 0.82 | ALDH1A1 (0.46) | HSP90AA1NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4735238 | 0.82 | HSP90AA1 (0.59) | HSP90AA1NPC1RAB9ARUNX1CRHR1 | |
| SCHEMBL14615313 | 0.81 | HSP90AA1 (0.58) | HSP90AA1NPC1RAB9ARUNX1CRHR1 | |
| SCHEMBL6130670 | 0.79 | HSP90AA1 (0.56) | HSP90AA1NPC1RAB9ARUNX1SMN1; SMN2 | |
| SCHEMBL7766604 | 0.78 | NPC1 (0.51) | HSP90AA1NPC1RAB9ARUNX1SMN1; SMN2 | |
| Dipyridyl SCHEMBL9014402 | 0.78 | CCR1 (0.77) | HSP90AA1NPC1RAB9ARUNX1SMN1; SMN2 | |
| Dipyridyl SCHEMBL9014122 | 0.78 | CCR1 (0.77) | HSP90AA1NPC1RAB9ARUNX1SMN1; SMN2 | |
| SCHEMBL2711382 | 0.78 | CCR1 (0.77) | HSP90AA1NPC1RAB9ARUNX1SMN1; SMN2 | |
| SCHEMBL8513636 | 0.77 | HSP90AA1 (0.54) | HSP90AA1NPC1RAB9ARUNX1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1909912-B1 | Use of collismycin A as oxidative stress inhibitor | NOSCIRA SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-1909912-B1 | Use of collismycin A as oxidative stress inhibitor | NOSCIRA SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2444121-A1 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | Noscira, S.A. (ES) | 2012-04-25 | — | — | EP | disclosed |
| EP-2444121-A1 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | Noscira, S.A. (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-8067441-B2 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | NEUROPHARMA, S.A. (ES) | 2011-11-29 | — | — | US | disclosed |
| US-8067441-B2 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | NEUROPHARMA, S.A. (ES) | 2011-11-29 | — | — | US | disclosed |
| US-8067441-B2 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | NEUROPHARMA, S.A. (ES) | 2011-11-29 | — | — | US | disclosed |
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| EP-1909912-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | Neuropharma S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007017146-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017146-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| EP-1749552-A1 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | Neuropharma S.A. (ES) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | PARK7, HSPA9, NLN | HSP90AA1 179/4885NPC1 311/4885RAB9A 1201/4885 |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | PARK7, HSPA9, NLN | HSP90AA1 179/4885NPC1 311/4885RAB9A 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.